Open Access Open Access  Restricted Access Subscription or Fee Access

Risperidone: A Silver Lining In Mental Disorders

Nikita Gurav, Dhanshree Patil, Shweta Patil, Sayali Nejkar

Abstract


Risperidone (RYKINDO®) is second generation benzisothiazole which elevates linkage to serotonin type 2 (5HT2A) and dopamine type 2(D2) receptor developed by Luye Pharma Group used in short term palliative treatment of aggression or psychopathic disorders. Both 5HT2 antagonism with D2 receptor, it selectively bind to 5HT2A antagonist and shows neuroleptic effect by Risperidone. It is also available in the form of oral solution and disintegrating tablet etc. It is long acting injectable formulation approved atypical antipsychotic risperidone and used for treatment of schizophrenia and bipolar disorder in adult.On 15 January 2023, FDA accepted Risperidone for treatment of schizophrenia in grown up, and as mono treatment and augmentation therapy to lethane and valproic acid sodium salt for treatment of schizophrenia and bipolar disorder, it is an atypical antipsychotic drug injected one time every twice week. The U.S. FDA has approved Risperidone for extended release injectable suspension. Phase III development is underway worldwide. This article summarize different aspects of Risperidone as API used to improve mental health. For instance, it has been the subject of open clinical trials for the treatment of bipolar disorder, schizophrenia in youth, and as a monotherapy or adjunctive treatment to Lithane or Valproic acid sodium salt for the continuation of manic depression therapy. It is also used as an antipsychotic medication for the treatment of juvenile mental disorders, in children with neurodevelopmental disorders, and in children with attention deficit or hyperkinetic syndrome behavior disturbances. In another trial, risperidone was tested in 101 children with autism disorder; in this instance, risperidone improved irritability and autism-related behavioral disorders.


Keywords


RYKINDO®, Risperidone, Schizophrenia disorder, Mental health, Antipsychotic drug.

Full Text:

PDF

References


PERSERIS® (risperidone) HCP. (n.d.). Retrieved from https://www.perserishcp.com/prescribing-information.pdf

RISPERDAL- risperidone tablet. (n.d.). Retrieved from DAILYMED: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia. (2023, April 12). Retrieved from Clinicaltrials.gov: https://classic.clinicaltrials.gov/ct2/show/NCT04072354

C. Leucht, S. H. (2011, April 1). Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials. Retrieved from SEMANTIC SCHOLAR : https://www.semanticscholar.org/paper/Oral-versus-depot-antipsychotic-drugs-for-critical-Leucht-Heres/2427f71510c9de459052f22def75d614c4300b2d

Drug Usage Statistics, United States, 2013 - 2020. (n.d.). Retrieved from ClinCalc.com: https://clincalc.com/DrugStats/Drugs/Risperidone

Möller, Hans-Jürgen. "Risperidone: a review." Expert opinion on pharmacotherapy 6.5 (2005): 803-818.

FDA Approves the First Drug to Treat Irritability Associated with Autism, Risperdal. (2006, October 6). Retrieved from US Food and Drug administration: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759.htm

From Wikipedia, the free encyclopedia. (n.d.). Retrieved from PubMed: https://en.wikipedia.org/wiki/PubMed#PubMed_identifier

Ira D. Glick, M., Christoph U. Correll, M., A. Carlo Altamura, M., Stephen R. Marder, M., John G. Csernansky, M., Peter J. Weiden, M and John M. Davis, M. (2011, december 15). Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia: A Data-Driven, Personalized Clinical Approach. Retrieved from Phsychiatrist.com: https://www.psychiatrist.com/jcp/schizophrenia/psychotic-disorders/mid-term-long-term-efficacy-effectiveness-antipsychotic/

Jan M . Brauner, S. H. (2014). Risperidone inhibits voltage-gated sodium channels. In Europian Journal Of Pharmacology (pp. 100-106).

Joseph biederman, p. h. (2008, february). Risperidone treatment for ADHD in children and adolescents with bipolar disorder. Retrieved from Pub Med Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515893/

Katja Komossa, c. r.-k. (2011 , january 19). Risperidone versus other atypical antipsychotics for schizophrenia. Retrieved from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167865/

L Ereshefsky, S. R. (n.d.). Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. Retrieved from Pub Med Central: https://pubmed.ncbi.nlm.nih.gov/6143748/

Luye Pharma : Receives Clinical Trial Approval in Europe for Its Innovative Formulation Paliperidone Palmitate Long-acting Injection ... (n.d.). Retrieved from marketscreener.com: https://www.marketscreener.com/quote/stock/LUYE-PHARMA-GROUP-LTD-16860092/

Luye Pharma Announces Innovative Drug - Risperidone Extended Release Microspheres for Injection has Reached Final Stage of NDA Process. (2018, dec 13). Retrieved from Biospace.com: https://www.biospace.com/article/releases/luye-pharma-announces-innovative-drug-risperidone-extended-release-microspheres-for-injection-has-reached-final-stage-of-nda-process/

Luye Pharma's Risperidone gets NDA filing acceptance by USFDA. (2019, may 23). Retrieved from biospectrumasia.com: https://www.biospectrumasia.com/news/34/13577/luye-pharmas-risperidone-gets-nda-filing-acceptance-by-usfda.html

Luye Pharma's Risperidone® NDA Filing Accepted by the U.S. FDA. (2019, may 30). Retrieved from market insider.com: https://markets.businessinsider.com/news/stocks/luye-pharma-s-risperidone-nda-filing-accepted-by-the-u-s-fda-1028240845

Nevena Divac, M. p. (2014, june 3). Second-Generation Antipsychotics and Extrapyramidal Adverse Effects. Retrieved from Pub Med Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065707/

Newton, W. (2023, April 13). Schizophrenia: Four major clinical trials to watch in 2023. Retrieved from Clinical Trials Arena: https://www.clinicaltrialsarena.com/features/features-schizophrenia-trials-to-watch/#:~:text=As%20the%20search%20for%20new,shift%20the%20drug%20development%20landscape

RISPERDAL CONSTA 25 mg powder and solvent for prolonged-release suspension for injection. (n.d.). Retrieved from emc: https://www.medicines.org.uk/emc/product/1690/smpc

RISPERDAL®. (n.d.). Retrieved from accessdata.fda.gov: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020272s085,020588s072,021444s058lbl.pdf

Risperidone. (n.d.). Retrieved from Drugs.com: http://www.drugs.com/monograph/risperidone.html

Risperidone (International). (n.d.). Retrieved from Drugs.com: https://www.drugs.com/international/risperidone.html

Risperidone and paliperidone. ( 2009). In C. B. Alan F. Schatzberg, The American psychiatric (p. 627).

RISPERIDONE. (2023). Retrieved from rxlist.com: https://www.rxlist.com/risperidone-drug.htm

RISPERIDONE® (risperidone) for extended-release injectable suspension, for. (n.d.). Retrieved from file:///C:/Users/HP/Downloads/212849s000lbl%20(2)%20(2).pdf

Valsamma Eapen, M. A. (2005). Risperidone Treatment in 12 Children With Developmental Disorders and Attention-Deficit/Hyperactivity Disorder. Retrieved from Pub Med Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1257406/




DOI: https://doi.org/10.37591/rrjodfdp.v10i3.1375

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research & Reviews: A Journal of Drug Formulation, Development and Production